Breast Cancer Treatment
Dear Southern Health and Social Care Trust (Northern Ireland),
I would like to please request the following information with regards to Breast Cancer Treatment, on behalf of Novartis.
The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.
Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:
• Abemaciclib (Verzenios) + aromatase inhibitor *
• Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
• Alpelisib (Piqray) + Fulvestrant (Faslodex)
• Atezolizumab (Tecentriq)**
• Bevacizumab (Avastin)
• Eribulin (Halaven)
• Everolimus (Afinitor) + Exemestane
• Fulvestrant (Faslodex) as a single agent
• Gemcitabine + paclitaxel
• Herceptin (Trastuzumab) + paclitaxel
• Herceptin (Trastuzumab) as a single agent
• Lapatinib (Tyverb)
• Neratinib (Nerlynx)
• Olaparib (Lynparza)
• Palbociclib (Ibrance) + aromatase inhibitor*
• Palbociclib (Ibrance) + Fulvestrant (Faslodex)
• Pertuzumab (Perjeta) + trastuzumab + docetaxel
• Ribociclib (Kisqali) + aromatase inhibitor*
• Ribociclib (Kisqali) + Fulvestrant (Faslodex)
• Talazoparib (Talzenna)
• Trastuzumab emtansine (Kadcyla)
• Other active systemic anti-cancer therapy **
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent
Q2. For the above patients, how many of these received their first ever dose for each product line?
Sincerely thank you for taking the time to answer these questions.
Yours faithfully,
Ben Holdsworth
Thank you for your email.
We acknowledge receipt of your request.
You will be aware of the significant pressures on our health and social
care services during the current surge of the Covid-19 pandemic. During
this time we have been asking our staff to prioritise their professional
caring duties and to support front line health and social care services in
responding to the emergency. This has understandably had an impact on
other duties within their role such as responding to legislative
requirements under FOI and the processing of Subject Access Requests.
We assure you that your request will be logged and processed, and we will
do our utmost to respond as quickly as possible.
Yours faithfully
Information Governance Team
Dear Mr Holdsworth,
Please see attached response in respect of your recent FOI request to the Southern Health and Social Care Trust.
We apologise for the delay.
Kind regards
Gail Fegan
Information Governance Officer
We work to defend the right to FOI for everyone
Help us protect your right to hold public authorities to account. Donate and support our work.
Donate Now